What is APLM's P/E ratio?

Apollomics Inc. Class A Ordinary Shares (APLM) currently trades at a P/E ratio of 24.17.

Apollomics Inc. Class A Ordinary Shares reports a Return on Equity (ROE) of 1,220.73%.

What is APLM's dividend yield?

Apollomics Inc. Class A Ordinary Shares offers a dividend yield of 0.00%.

What is APLM's Quality Score?

Our AI rates APLM's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy APLM?

Our AI Timing Score for APLM is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does APLM belong to?

Apollomics Inc. Class A Ordinary Shares is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Apollomics Inc. Class A (APLM) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

APLM AI Analysis Summary

Our AI summary for APLM: Apollomics Inc. Class A Ordinary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 24.17, ROE of 1,220.73%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

APLM

Apollomics Inc. Class A Ordinary Shares

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 17.28

-0.30 (-1.68%) Day Change

Watchlist Portfolio Compare Chart

24.17

P/E

-0.07

D/E

1,220.7%

ROE

-579.6%

ROA

0.00%

Div Yield

-0.41

PEG

APOLLOMICS INC. CLASS A ORDINARY SHARES
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 17.28 Price -0.30 (-1.68%) Day Change	NEWS SCORE: N/A

APLM, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	17.28
PBV / Sector	-12.11 / 44,105.10
Earning Per Share	-17.42

PE / Sector	24.17 / 19.37
PEG or PE/Growth / Sector	-0.41 / 1.06
Average 1M Daily Value	0.82 M GREAT
Average 1W Daily Value	1.52 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-586.19 / 97.23
NPM Average (%) / Sector	-24,698.73 / -1,697.84
NPM Change Average (%) / Sector	53.39 / 5,097.59 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-579.64 / 185,260.64
ROA Average (%) / Sector	-356.06 / 36,684.64
ROA Change Average (%) / Sector	56.58 / 422,221.42 GREAT
ROE (%) / Sector	1,220.73 / 243,761.81
ROE Average (%) / Sector	18.35 / 48,758.38
ROE Change Average (%) / Sector	-147.41 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:38
Symbol	APLM
Name	APOLLOMICS INC. CLASS A ORDINARY SHARES
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	2.20 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	38.60 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 989 East Hillsdale Blvd., Foster City, CA, United States, 94404

Phone: 650 209 4055

Website: https://www.apollomicsinc.com

Sector: Healthcare >> Biotechnology

Description: Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.